in 2021 years 10 month 15 In a series of rulings handed down in Japan, The Paris Court of Appeal upheld the National Office for Industrial Property (INPI) Earlier decision, The drug licensing investment Corporation was dismissed Royal Pharma The diabetes treatment sitagliptin (sitagliptin) , Alogliptin (alogliptin) , Ligliptin (linagliptin) , Saxagliptin (saxagliptin) And Vogliptin (vildagliptine) The supplementary protection certificate (SPC) Apply for.
SPC It is used to extend the protection period of drug patents, But not more than that 5 years. SPC Applicable to specific products that have been authorized for use by regulators (Pharmaceutical or pesticide products) , Designed to compensate innovators for delays in bringing their products to market due to marketing approval, The shortening of the actual term of protection of a patent.
Reprinted from China Intellectual Property Network
disclaimer: This website reprint articles are from the Internet, Does not represent the views of this website or confirm the authenticity of its content. If the source is mislabeled or the copyright of the article is involved, Please contact this website, This website will be corrected in due course, delete, thank you.
Patent infringement rights protection
France, European Union
France, European Union
